K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.81 CAD -0.68% Market Closed
Market Cap: 578.9m CAD

Intrinsic Value

The intrinsic value of one GUD stock under the Base Case scenario is 4.7 CAD. Compared to the current market price of 5.81 CAD, Knight Therapeutics Inc is Overvalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GUD Intrinsic Value
4.7 CAD
Overvaluation 19%
Intrinsic Value
Price
K
Worst Case
Base Case
Best Case

Valuation History
Knight Therapeutics Inc

Valuation History Unavailable

Historical valuation for GUD cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare GUD to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GUD?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Knight Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Knight Therapeutics Inc

Current Assets 454m
Cash & Short-Term Investments 160m
Receivables 146.4m
Other Current Assets 147.6m
Non-Current Assets 549m
Long-Term Investments 87.5m
PP&E 21m
Intangibles 363.1m
Other Non-Current Assets 77.5m
Efficiency

Free Cash Flow Analysis
Knight Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Knight Therapeutics Inc

Revenue
372.8m CAD
Cost of Revenue
-205.2m CAD
Gross Profit
167.6m CAD
Operating Expenses
-168.4m CAD
Operating Income
-800k CAD
Other Expenses
11.9m CAD
Net Income
11.1m CAD
Fundamental Scores

GUD Profitability Score
Profitability Due Diligence

Knight Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
44/100
Profitability
Score

Knight Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

GUD Solvency Score
Solvency Due Diligence

Knight Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Low D/E
Short-Term Solvency
63/100
Solvency
Score

Knight Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 7.72 CAD with a low forecast of 6.06 CAD and a high forecast of 9.45 CAD.

Lowest
Price Target
6.06 CAD
4% Upside
Average
Price Target
7.72 CAD
33% Upside
Highest
Price Target
9.45 CAD
63% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Knight Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GUD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one GUD stock?

The intrinsic value of one GUD stock under the Base Case scenario is 4.7 CAD.

Is GUD stock undervalued or overvalued?

Compared to the current market price of 5.81 CAD, Knight Therapeutics Inc is Overvalued by 19%.

Back to Top